Core Viewpoint - The company has observed an increase in share price and trading volume on specific dates in late October and early November 2025, but the board is unaware of any reasons for these changes or any undisclosed information that could affect the market [1] Group 1 - The board confirmed that the company's business operations remain normal and that there have been no significant changes in the business or financial status as of the announcement date [1] - A wholly-owned subsidiary, Shanxi Tuo Yun Biotechnology Co., Ltd., signed a strategic cooperation agreement on October 23, 2025, with three companies for a procurement deal valued at no less than RMB 1 billion for Rhizoclonium and related products from 2026 to 2028 [1] - The specific commercial terms such as pricing, quantity, and delivery methods are yet to be negotiated, and a formal procurement agreement has not been signed [1]
透云生物 回应股价异动 全资附属签 10 亿元莱茵衣藻采购框架协议